Contribute Try STAT+ Today

After two years of wrangling, AbbVie (ABBV) agreed to pay $24 million to settle a lawsuit filed by the California insurance commissioner, who accused the drug maker of paying kickbacks to doctors and using a stealthy network of nurses to illegally boost prescriptions of its best-selling Humira treatment.

Over a five-year period, the drug maker offered physicians a familiar menu of tempting items, from cash, meals, and drinks, to gifts and trips, along with patient referrals, in hopes they would write more prescriptions for the rheumatoid arthritis medicine, according to the lawsuit. Humira is a franchise product for AbbVie and last year generated $14.8 billion in sales in the U.S. alone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy